Dexamethasone sodium phosphate is under clinical development by Quince Therapeutics and currently in Phase III for Ataxia-Telangiectasia (Louis-Bar Syndrome). According to GlobalData, Phase III drugs for Ataxia-Telangiectasia (Louis-Bar Syndrome) does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Dexamethasone sodium phosphate LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Dexamethasone sodium phosphate overview

Dexamethasone sodium phosphate is under development for the treatment of ataxia telangiectasia, non ambulatory ataxia telangiectasia and Duchenne muscular dystrophy (DMD). It is administered through intravenous route and acts by targeting glucocorticoid receptor. The drug candidate comprises of dexamethasone sodium phosphate (DSP) encapsulated in autologous red blood cells and is being developed based on AIDE technology.
The therapeutic candidate was also under development for the treatment of the Crohn's disease, cystic fibrosis, ulcerative colitis, chronic obstructive pulmonary disease, other chronic inflammatory diseases.

Quince Therapeutics overview

Quince Therapeutics (Quince) is a clinical-stage biopharmaceutical company that focused on novel therapeutic approaches to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases. The company product pipeline includes NOV004. The company lead candidate NOV004 is an anabolic peptide engineered to precisely target and concentrate at the bone fracture site. Quince also runs clinical trails such as GAIN Trial, a Phase 2 and Phase 3 clinical trial of COR388 to moderate and treat Alzheimer’s disease. Quince is headquartered in South San Francisco, California, the US.

For a complete picture of Dexamethasone sodium phosphate’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.